Prolexys Pharmaceuticals Raises $20M

Salt Lake City-based Prolexys Pharmaceuticals announced Thursday that it has raised $20M in a Series A1 funding round. The round was led by Friedli Corporate Finance, as well as Peter Friedli, chairman of Prolexys. Prolexys is developing a novel small molecule drug targeted at treating colon, lung, pancreatic, and ovarian cancer. Prolexys Pharmaceuticals said it currently has a compound in Phase 1 studies. More information »